CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling - Wikidata - awgldk - TriplyDB

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

http://www.wikidata.org/entity/Q24672058

about

Targeted therapies in sarcomas: challenging the challenge Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas Neoplasia: Where We Have Been and Where We Are Going Temsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF expression Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy Neoplasia: the second decade.EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies Development of HIF-1 inhibitors for cancer therapy MicroRNAs in Muscle: Characterizing the Powerlifter Phenotype.Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/Akt/mTOR/HIF-1 alpha/VEGF pathway.GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.Novel and emerging targeted-based cancer therapy agents and methods.Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells.Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors Adult human sarcomas. II. Medical oncology.Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1.Biomarkers in clear cell renal cell carcinoma.Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics.Targeting the hypoxia-inducible factor (HIF) pathway in cancer.Current and future directions in mammalian target of rapamycin inhibitors development.Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor.Targeted therapy in bone and soft tissue sarcoma in children and adolescents.Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery.Current and future management strategies for relapsed or progressive hepatoblastoma.Recent agents targeting HIF-1α for cancer therapy.Insulin-like growth factor-binding protein-6 and cancer.

P2860

Q21285014-7E3C5761-2F55-447D-9A9B-255C6129E7AF Q26825000-C2676F45-2BBD-422D-BAD3-C43206DE7AFD Q28395095-CBD35CD2-2CAE-4695-8D30-C6369D6801C2 Q28540142-365D4B99-2D65-471C-AE66-1BAAC44CA47E Q30419679-8F400B87-AAC3-426D-97DF-FB2181890ACD Q30484000-333417F7-656D-41DD-A3F1-705CD9A7CA00 Q33273472-1062B14C-5503-49D5-8EE1-0AB48C14347C Q33397833-4F2CFE21-B4BE-4032-9D9F-0A47D3EA3403 Q33411585-30A80AAA-D7C4-4267-9951-F9A4A6F641C5 Q33435808-5FC9DEF4-FB54-4715-9CB4-8639B94AA6C1 Q33514778-ADE9A25E-F01E-47A0-AB3A-1E90E166A755 Q33559468-8E424E43-9D50-4BA1-A4E3-664A4B124F2D Q33703381-4E98DB1E-ED58-478B-B379-BA7896604199 Q33770477-45ABE7BB-B276-4E21-9004-433493D44823 Q35060705-C5F7BABF-2A62-4B0B-8D25-701D70019341 Q35067950-AD216074-956C-4DC0-B845-03720A3D0D2C Q35096201-C8393F8F-A0CD-467C-B28E-91C1A36BD800 Q35112340-85C2AAE4-F3F5-4E65-B058-A09875DD4FBB Q35558057-0C32175B-9A63-4237-A4F2-C5E3935D1B3D Q36061770-9AA9EEAF-21DE-4945-A662-824C4034804B Q36144084-3E6D16F7-D8FF-4473-AA8E-D37E14F62E0A Q36425959-5A706DD4-A4D8-4189-833B-1D192B3FE2F3 Q36470446-C9DF29B0-0E39-4F07-A023-C3C45749CDDF Q36481029-6E431961-95FA-44B1-A284-4D27C67EC40F Q36731430-2446A7A6-30B3-46CA-B0AB-EEA0EA4603BE Q36865546-D5D8B30F-5C01-4E88-AE9A-35B522E4DA8E Q37025951-EC5353E0-68FD-4B25-B8BA-2674B2C3B480 Q37228059-DEC016D3-1676-4606-8384-D5A5099C4DD7 Q37301320-26D4ECBA-7CFE-4C28-8D13-B054E6A89509 Q37323038-104F9E1B-DB02-46E0-90DE-9D37BACB1F2C Q37379788-CB113AF7-0C2B-41F9-A6DE-DD8A0FF265EC Q37404658-C8FAF643-93CB-4334-A9F0-9FB94ED8C91D Q37587446-DBA55E78-BA04-43CE-9C65-1B914EA85578 Q37836904-1AE2AC07-B9B5-409C-9642-AA8479AFC3BD Q37864096-BFB92CCB-53F4-46A1-9B75-12EF8A160B47 Q37981129-4BDEED40-8DCA-4C20-A589-2A6D130C16D4 Q38000323-09F9E944-8E16-46AC-9D0E-8ABF831279D2 Q38019027-079E142F-A56A-44B0-9B04-29C6960780CB Q38042021-0B5E1701-BDDA-4BC8-9369-D98F756696F7 Q38057775-3C6DADEB-B890-4817-BBC2-7202C46D5216

P2860

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

http://www.wikidata.org/entity/Q24672058

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@ast

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@en

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@nl

type

label

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@ast

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@en

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@nl

prefLabel

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@ast

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@en

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@nl

P1433

Q24672058-85F3DBFE-C5D0-4AA3-B8C8-E2625B9CE177

P1476

Q24672058-2EE14AC9-5C2C-4450-8248-D0D4E6DADCE2

P2093

Q24672058-1393F4D3-100D-4D37-BEFE-99EE4466AFE4

Q24672058-566856E6-5260-43F1-8BF9-22D0DEAB3AF6

Q24672058-7DD63A39-9D56-4FA8-816B-07A4564F8CC4

Q24672058-ADC3E978-C78C-4CA2-8739-4BD82724A67B

Q24672058-BEA484D1-5710-49AE-AB65-F014856EF77A

P2860

Q24672058-01691DF5-8A2C-4C5B-B783-6773E659F4B6

Q24672058-02D52A98-2385-4DC6-8AC4-4F3186EBA39A

Q24672058-0477AB30-60F5-41A5-82C9-629FDACBF4C3

Q24672058-0662B7E5-DCD5-4140-88F5-0C77BD0E9224

Q24672058-06AFD89D-768D-4388-AEC6-5DB0ED00EB91

Q24672058-0F00D095-F86E-4033-B1DE-EDE1E44F0C06

Q24672058-1418834F-DC86-467A-92FB-56C1D1F7A6DC

Q24672058-14FB6FE3-EDF8-406A-B22E-8E4D3599C2D4

Q24672058-1D4D0D5B-B478-4097-9BD3-9902238DBBF8

Q24672058-22B066E1-5FF1-4D6A-8EB1-5ABAC275D3F3

P304

Q24672058-428A00AC-5BD9-456B-A994-E0481B871CB9

P31

Q24672058-8A05DADB-CDF4-494E-AA0C-2046F5F0B810

P3181

Q24672058-503D2177-CBA1-4AB3-A774-CF2BDA01BC41

P356

Q24672058-28C249CF-552C-4A18-850A-69196DCDD37E

P407

Q24672058-4FFE4BFA-0C51-4AC0-A88D-D2C9518C3550

P433

Q24672058-C329673E-6D7E-4A14-B366-291940C0761A

P478

Q24672058-F5864C89-09E8-455C-8AEF-A7ED359AC5AF

P577

Q24672058-7F040F5E-9235-4D60-8A4D-573400883351

P5875

Q24672058-8E051DB4-44EE-4704-932C-581404423EDF

P698

Q24672058-22225B53-56AA-4EE4-B728-A7C0B0F38E90

P921

Q24672058-23799F23-D753-4B95-8D3B-5EA440E81762

P932

Q24672058-918F17C8-8C96-4C23-8D25-E3F5FF9772A9

P3181

P356

P1433

P1476

CCI-779 inhibits rhabdomyosarc ...... mTOR/Hif-1alpha/VEGF signaling

@en

P2093

Arnulfo Mendoza

http://www.w3.org/2001/XMLSchema#string

Chand Khanna

http://www.w3.org/2001/XMLSchema#string

Lee J Helman

http://www.w3.org/2001/XMLSchema#string

Na Shen

http://www.w3.org/2001/XMLSchema#string

Xiaolin Wan

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Targeting HIF-1 for cancer therapy

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

Rapamycins: mechanism of action and cellular resistance

The TOR pathway: a target for cancer therapy

Role of angiogenesis in tumor growth and metastasis

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

P304

394-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4811073

http://www.w3.org/2001/XMLSchema#string

P356

10.1593/NEO.05820

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6994434

http://www.w3.org/2001/XMLSchema#string

P698

16790088

http://www.w3.org/2001/XMLSchema#string

P921

P932

1592447

http://www.w3.org/2001/XMLSchema#string